Clinical Trial Detail

NCT ID NCT02882282
Title Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

oral cavity carcinoma in situ

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.